This page is an English translation of the Korean original. If there is any discrepancy, the Korean version prevails.

Vascular haemophilia혈관혈우병

📋 Contents and key points
ItemDetails
A. Classification codesICD-10: D68.0 (vascular haemophilia) | Special Copayment Reduction: V009 (rare disease, 10% copayment for 5 years after registration)
B. SynonymsVascular haemophilia, angiohaemophilia, von Willebrand disease, pseudohemophilia, constitutional thrombopathy
C. Adult onsetPossibility of first manifestation in adulthood: very likely — Vascular haemophilia (= von Willebrand disease) type 1 accounts for 70-80% of the total and is the most common form of hereditary bleeding disorder in which mild bleeding symptoms are first identified in adulthood, triggered by surgery, childbirth, or tooth extraction; there are many adult cases first diagnosed in women because of heavy menstrual bleeding.
1. HistoryFrom von Willebrand's first description in 1926 to the establishment of the British term 'vascular haemophilia' and its listing as a synonym for ICD-10 D68.0
2. CausesVWF gene (12p13.3) variants; type 1 (quantitative deficiency, AD), type 2 (qualitative defect: 2A/2B/2M/2N), type 3 (complete deficiency, AR); acquired vWD
3. GeneticsVWF 12p13.3, 178kb, 52 exons; D'-D3 (FVIII binding), A1 (GPIbα), A3 (collagen); autosomal dominant/recessive; influence of blood group O; pseudogene on chromosome 22
4. General epidemiologyVariant carriers ~1%, symptomatic prevalence ~125 per million; most common hereditary bleeding disorder; type 3 1-3 per million
5. PathophysiologyIn vWF deficiency, reduced platelet adhesion + secondary reduction of FVIII:C; type 2B thrombocytopenia; type 2N defective FVIII binding
6. SymptomsEpistaxis, gum bleeding, bruising, heavy menstrual bleeding, bleeding after surgery/childbirth; type 1 mild, type 3 severe (joint bleeding possible)
7. SignsProlonged PFA-100/200 closure time, decreased vWF:Ag, decreased vWF:RCo, decreased FVIII:C (type 3 and type 2N), multimer analysis
8. ScreeningBleeding score (BAT), PFA-100, APTT (may be normal in mild cases), simultaneous measurement of vWF:Ag/RCo/FVIII:C
9. DiagnosisvWF:Ag + vWF:RCo + FVIII:C + multimer analysis + RIPA + vWF:FVIII binding (2N) + VWF NGS; blood group O correction
10. TreatmentDDAVP (effective in type 1, contraindicated in 2B), vWF concentrates (plasma-derived/recombinant Vonvendi), tranexamic acid, oral contraceptives
11. PrognosisNormal life expectancy for most type 1 and type 2; in type 3, joint damage is possible with recurrent joint bleeding
12. PreventionGenetic counseling, DDAVP response test, carrier VWF testing, prenatal diagnosis/PGT, planning before surgery or tooth extraction
13. Referencesvon Willebrand EA. Finska Läkaresällsk Handl. 1926 … and 9 other papers

1. History

Origin of the name 'Vascular haemophilia'

The name vascular haemophilia was a term adopted by British medicine in the early 20th century to describe a certain bleeding disorder, reflecting the recognition that the disease is distinct from classical hemophilia while having an abnormality of vascular components as its core feature. The British spelling haemophilia is distinguished from the American hemophilia and is still used as the official spelling of the medical term in the United Kingdom, Australia, New Zealand, and some European countries.

The historical starting point of this name goes back to the 1926 report of the Finnish internist Erik Adolf von Willebrand (1870-1949). Observing a large family on the Åland Islands of Finland over several decades, he identified a distinctive hereditary bleeding tendency in which women and men were equally affected, the platelet count was normal, but the bleeding time was markedly prolonged. Judging this disease to be qualitatively different from classical hemophilia A (then known to be X-linked recessive), he first announced it under the name hereditär pseudohemofili (hereditary pseudohemophilia).

Establishment of the term 'Vascular haemophilia' in British medicine

British hematology research in the 1950s and 1960s was world-class, and many papers describing bleeding disorders were published in the British Medical Journal (BMJ) and Lancet during this period. British researchers began to use the term vascular haemophilia widely, emphasizing the concept that the disease described by von Willebrand was due to an abnormality of the vascular endothelium. This term embodied the pathophysiological hypothesis of the time that deficiency or dysfunction of some substance secreted by vascular endothelial cells was the source of the hemostatic disorder.

The 1952 BMJ paper by Biggs et al. of Britain that identified Christmas disease (hemophilia B, FIX deficiency) was a milestone symbolizing the international influence of British hematology. British naming practice of this period had a considerable influence on the international literature, and the term vascular haemophilia also took root in this atmosphere.

1960s-1980s: identification of vWF and changes in nomenclature

From 1963 onward, it began to be revealed that the key deficient substance of this disease is a large multimeric glycoprotein synthesized and secreted by vascular endothelial cells and platelets. This protein was later named von Willebrand factor (vWF) after its discoverer. In 1971, Zimmermann et al. developed a technique to quantify vWF antigen (vWF:Ag) by immunoelectrophoresis, making it possible to measure vWF and FVIII coagulant activity separately. From this time, the term vascular haemophilia was gradually replaced as the international standard name by von Willebrand disease, named after the founder of the disease.

Complete cloning of the VWF gene was achieved in 1986. Subsequently, the domain structure of the vWF protein and the function of each domain (platelet GPIbα binding, collagen binding, FVIII binding) were elucidated in detail at the molecular level, making it clear that the pathophysiology of this disease is a quantitative or qualitative deficiency of a specific protein rather than a vague dysfunction of the vascular endothelium.

Official listing as a synonym in ICD-10, and the present

In the International Classification of Diseases (ICD-10), the code D68.0 covers von Willebrand disease as a whole, and vascular haemophilia (British spelling) is listed as an official synonym of this code. As a result, although it is not the main name used in modern clinical practice, vascular haemophilia is recognized as a legally valid diagnosis name for administrative, medical record, and insurance claim purposes.

In 2006, the ISTH/SSC formalized the current international standard classification system that classifies vWD into type 1 (partial quantitative deficiency), type 2 (qualitative defect: subtypes 2A/2B/2M/2N), and type 3 (complete deficiency). In 2019, Vonvendi (vonicog alfa), a recombinant vWF product, received US FDA approval, expanding treatment options. In the United Kingdom and Europe, British spelling is still officially used alongside, as in Haemophilia (capitalized, a journal name). The World Federation of Hemophilia (WFH) adopted American spelling from its early days, but the United Kingdom Haemophilia Centre Doctors' Organisation (UKHCDO) and others still adhere to the spelling haemophilia, and the two spelling systems coexist. Within this historical context, Vascular haemophilia has taken its place as one of the most classical historical synonyms of von Willebrand disease.


2. Causes

VWF gene variants and vWF abnormalities

The cause of vascular haemophilia (that is, von Willebrand disease) is deficiency or dysfunction of von Willebrand factor (vWF) due to variants of the VWF gene (chromosome 12p13.3). vWF is produced and secreted by vascular endothelial cells (stored in Weibel-Palade bodies) and platelets (stored in α-granules), and forms large multimeric structures in plasma. vWF has two main functions. First, after binding to subendothelial collagen exposed at the time of vascular injury, it mediates platelet capture through platelet GPIbα and GPIIb/IIIa. Second, it binds non-covalently to FVIII in plasma, protecting FVIII from proteolytic attack and prolonging its half-life.

Causes by vWD classification

vWD type 1 (partial quantitative deficiency) accounts for about 70-80% of all vWD and is mainly inherited as autosomal dominant (AD). Owing to missense variants, splice-site variants, and promoter variants of the VWF gene, vWF:Ag is reduced to 30-50%, and vWF function is reduced proportionally. Expressivity and penetrance are variable, so the severity of bleeding symptoms may differ even within a family carrying the same variant.

vWD type 2 (qualitative defect) is subdivided into four subtypes. Type 2A has reduced platelet binding function due to loss of high-molecular-weight multimers; type 2B, due to A1 domain variants, causes excessive binding of vWF to GPIbα, resulting in thrombocytopenia and loss of high-molecular-weight multimers. Type 2M has a normal multimer structure but specifically reduced platelet binding function, and in type 2N, D'-D3 domain variants selectively abolish FVIII binding capacity. vWD type 3 (complete deficiency) is inherited as autosomal recessive (AR), with vWF almost completely absent and FVIII:C also severely reduced to 1-10%.

Acquired von Willebrand syndrome

Although rare, non-hereditary acquired vWD (acquired von Willebrand syndrome) can also occur. It arises by mechanisms such as shear stress degradation of vWF due to vascular stenosis (aortic valve stenosis, left ventricular assist device), absorption of vWF by tumors such as lymphoma and myeloma, and formation of vWF autoantibodies in autoimmune diseases. Treatment of the underlying disease is the key in acquired vWD.


3. Genetics

VWF gene structure

The VWF gene is located on chromosome 12p13.3 and consists of a total length of about 178kb and 52 exons. Mature vWF consists of a mature protein of 2,050 amino acids (precursor 2,813 amino acids) and forms a complex multimeric structure. The main functional domains of the vWF protein are as follows.

Mode of inheritance and influence of blood group

vWD types 1 and 2A/2B/2M are mainly inherited as autosomal dominant, with variable expressivity. Types 2N and 3 are inherited as autosomal recessive. Individuals with blood group O have vWF:Ag measured on average 25% lower than other blood groups. This is because blood group antigens affect the glycosylation pattern of vWF and thereby determine its plasma half-life. Therefore, when a mild decrease in vWF:Ag is observed in a patient with blood group O, blood group correction is needed to differentiate clinically significant vWD from a low-normal variant.

Pseudogene and precautions in molecular diagnosis

On chromosome 22 there is a pseudogene (VWF pseudogene) with about 97% similarity to exons 51-52 of the VWF gene. This pseudogene can be confused with true VWF variants in conventional short-read PCR-based Sanger sequencing and is a cause of misdiagnosis. Therefore, in VWF gene analysis, the true VWF gene must be selectively amplified using long-range PCR, or the two sequences must be distinguished by haplotype analysis. This must also be taken into account when designing next-generation sequencing (NGS) panels.


4. General epidemiology

Prevalence and worldwide distribution

Von Willebrand disease (vascular haemophilia) is the most common hereditary bleeding disorder. Molecular genetic studies in the general population estimate that the carrier rate of VWF gene variants reaches about 1%, but the prevalence with clinically significant bleeding symptoms is reported as about 100-125 per million. This difference is because, in many cases, variant carriers show only mild symptoms or remain asymptomatic and undiagnosed.

The prevalence itself is equal in men and women, but the diagnosis rate is relatively higher in women owing to the additional bleeding burden of heavy menstrual bleeding. vWD type 1 accounts for about 70-80% of the total, type 2 subtypes (2A/2B/2M/2N) for 15-25%, and type 3 is the rarest at about 1-3 per million. Because type 3 vWD is autosomal recessive, its prevalence tends to be relatively high in populations with frequent consanguineous marriage or in small founder populations.

Epidemiology in Korea and Special Copayment Reduction status

In Korea, precise registration statistics by vWD subtype have not yet been fully established, but data continue to accumulate through hemophilia treatment centers and rare disease registries. Through registration for rare disease Special Copayment Reduction (V009), a 10% copayment of medical care benefit costs applies for 5 years, which plays an important role in reducing patients' medical cost burden. In Korea as well, there are not a few adult-onset cases leading to diagnosis in which women are first diagnosed because of heavy menstrual bleeding, or in which a prolonged APTT or decreased vWF:Ag is found incidentally in preoperative testing.


5. Pathophysiology

Impaired platelet adhesion-mediating function

When a blood vessel is injured, subendothelial collagen is exposed, and plasma vWF rapidly binds to collagen through the A3 domain. Bound vWF unfolds structurally under high shear stress, exposing the A1 domain, which binds platelet GPIbα and mediates initial platelet capture and adhesion. When vWF is deficient or A1 domain function is reduced (types 2A, 2B, 2M), this process is impaired and platelet plug formation becomes insufficient. Because vWF-dependent platelet adhesion is especially important in small vessels and capillaries with high shear stress, mucocutaneous bleeding (epistaxis, gum bleeding, heavy menstrual bleeding) is prominent in vWD patients.

Loss of FVIII-stabilizing function

Normally, FVIII in plasma circulates bound to vWF, and vWF protects FVIII from premature degradation by proteases (APC, FXa, thrombin, etc.). When vWF is decreased (types 1 and 3) or FVIII binding capacity is lost (type 2N), the plasma half-life of FVIII is shortened from 12-14 hours to 2-6 hours and FVIII:C is secondarily decreased. The decrease in FVIII:C impairs formation of the tenase complex (FVIIIa-FIXa) in the intrinsic coagulation pathway and delays thrombin generation, making reinforcement of the platelet plug by the fibrin mesh insufficient.

Special mechanism of vWD type 2B: thrombocytopenia

In vWD type 2B, owing to variants of the A1 domain, vWF tends to bind spontaneously to platelet GPIbα even without shear stress. As a result, platelets are captured by vWF and cleared early by the reticuloendothelial system, and thrombocytopenia occurs in peripheral blood. In addition, high-molecular-weight multimers are preferentially consumed, so plasma high-molecular-weight multimers are decreased. Thrombocytopenia may worsen in situations where vWF secretion increases, such as pregnancy or inflammation. DDAVP administration is contraindicated in this subtype because DDAVP further promotes vWF secretion and may worsen thrombocytopenia.


6. Symptoms

Mucocutaneous bleeding: the typical symptom of vascular haemophilia

The most typical symptom of vascular haemophilia (von Willebrand disease) is mucocutaneous bleeding. This reflects reduced platelet adhesion in small vessels. The most common symptoms are recurrent epistaxis (nosebleeds), gum bleeding, skin bruising (purpura), and excessive bleeding after wounds. In patients with mild type 1, these symptoms are within the range of everyday life, so it is common for the disease to go undiagnosed until adulthood.

Female-specific symptoms: heavy menstrual bleeding and postpartum hemorrhage

In female patients, heavy menstrual bleeding (menorrhagia) is the representative symptom. vWD should be suspected if menstrual flow has been excessive since menarche, menstruation lasts 7 days or more, or clots (coagulated lumps) are included. Not a few female vWD patients mistake it for 'having always had heavy periods by constitution' and are first diagnosed on the occasion of surgery or pregnancy and childbirth. Postpartum hemorrhage after delivery is an important bleeding complication of vWD; in particular, even if vWF:Ag is physiologically elevated immediately after delivery, it decreases sharply several days after delivery, so delayed postpartum hemorrhage can occur.

Excessive bleeding after surgery or tooth extraction, and special symptoms of severe subtypes

When excessive bleeding occurs after invasive procedures such as surgery, tooth extraction, or endoscopic biopsy, it can also be the occasion on which previously unknown vWD first becomes clinically apparent. In type 1 of moderate or greater severity and in type 3, gastrointestinal bleeding can be a problem, and when angiodysplasia is accompanied, recurrent gastrointestinal bleeding becomes a serious complication. In vWD type 3, both vWF and FVIII:C are severely decreased, and spontaneous joint bleeding or intramuscular hematoma can occur, resembling the severe phenotype of hemophilia A.


7. Signs

Overview of laboratory findings

Laboratory findings of vascular haemophilia (von Willebrand disease) vary by subtype. It is important to distinguish the key findings to be considered in all subtypes from the findings specific to each subtype.


8. Screening

Clinical screening using the Bleeding Assessment Tool (BAT)

The most important first step in screening for vascular haemophilia is taking a structured bleeding history. The Bleeding Assessment Tool (BAT) recommended by the International Society on Thrombosis and Haemostasis (ISTH) standardizes and scores multiple items such as epistaxis, gum bleeding, bleeding after surgery, bleeding after tooth extraction, bruising, skin bleeding, gastrointestinal bleeding, heavy menstrual bleeding, and postpartum hemorrhage. vWD testing is recommended if BAT is ≥5 points in women or ≥3 points in men. The BAT is not only a tool for deciding whether to refer for testing, but is also useful for quantitatively tracking the severity of symptoms.

Basic screening test panel

When vWD is clinically suspected, it is recommended to perform the following basic screening tests at the same time.

Even if the result of a single test is negative, the physiological state at the time of testing (pregnancy, inflammation, exercise, estrogen use, etc.) can transiently raise vWF, so when there is strong clinical suspicion, it is important to repeat the test at a different time.


9. Diagnosis

Stepwise diagnostic algorithm

The final diagnosis and subtype classification of vascular haemophilia (von Willebrand disease) are made through the following systematic steps.

Step 1 — Basic screening tests: Measure vWF:Ag, vWF:RCo (GPIbA or GPIbM method), FVIII:C, PFA-100/200 closure time, platelet count, and APTT simultaneously. Be sure to check whether the blood group is O, and apply O-corrected reference values when interpreting test results.

Step 2 — vWF multimer analysis: Analyze the distribution of low-, intermediate-, and high-molecular-weight multimers by electrophoresis. Type 1: proportional decrease of all multimers. Type 2A: loss of high- and intermediate-molecular-weight multimers. Type 2B: loss of high-molecular-weight multimers (similar to type 2A but differentiated by RIPA). Types 2M and 2N: normal multimer pattern.

Step 3 — Subtype-differentiating specific tests: RIPA (ristocetin-induced platelet aggregation) — in type 2B, platelet aggregation occurs even at low-concentration ristocetin (0.5-0.7mg/mL). vWF:FVIII binding assay (ELISA) — binding capacity below 30% in type 2N. Collagen binding assay (vWF:CB) — useful for differentiating type 2M.

Step 4 — VWF gene analysis (NGS): Performed when subtype differentiation is unclear from clinical and laboratory findings or when carrier testing within the family is needed. The entire VWF gene is analyzed by NGS, and long-range PCR-based sequencing or haplotype analysis is essential to avoid pseudogene interference. Once a VWF variant is confirmed, screening within the family and genetic counseling become possible.

Summary table of laboratory findings by aWD subtype

Test itemType 1Type 2AType 2BType 2MType 2NType 3
vWF:AgDecreasedDecreased to normalDecreased to normalDecreased to normalNormal to mildly decreasedNear 0
vWF:RCoDecreasedDecreasedDecreasedDecreasedNormalNear 0
RCo/Ag ratio≥0.6<0.6<0.6<0.6NormalNot measurable
FVIII:CMildly decreasedNormal to mildNormal to mildNormalReduced (1–40%)Severely decreased
Multimer analysisOverall decreaseHMW lossHMW lossNormalNormalAlmost none
RIPA (low concentration)DecreasedDecreasedHyperresponseDecreasedNormalDecreased
Platelet countNormalNormalPossibly decreasedNormalNormalNormal
vWF:FVIII bindingNormalNormalNormalNormalMarkedly decreasedNot measurable

10. Treatment

DDAVP (desmopressin): first-line treatment for type 1

DDAVP (1-deamino-8-D-arginine vasopressin) is a synthetic vasopressin derivative that stimulates Weibel-Palade bodies of vascular endothelial cells to release vWF and FVIII into plasma. It is administered by subcutaneous injection, intravenous injection, or intranasal spray (high concentration, 150-300μg). It is most effective in vWD type 1, and within 30-60 minutes after administration vWF:Ag and FVIII:C rise to 2-4 times baseline, providing sufficient hemostatic effect for minor bleeding and minor surgery. However, with repeated administration within 48-72 hours, tachyphylaxis occurs as the response weakens owing to depletion of storage pools, so switching to a vWF concentrate is necessary for major or long-duration surgery. Contraindicated in type 2B — DDAVP further promotes secretion of already overactivated vWF and may worsen thrombocytopenia. In types 2M and 2N, therapeutic effect is limited, so a prior response test is essential.

vWF concentrates

This method directly replaces exogenous vWF with intact FVIII binding capacity. Plasma-derived vWF concentrates (Haemate P, Wilate, Alphanate, etc.) are purified from virus-inactivated plasma pools and contain both vWF and FVIII. Recombinant vWF (Vonvendi/Veyvondi, vonicog alfa) is a recombinant vWF product that received US FDA approval in 2019; compared with plasma-derived products, it carries no risk of infection transmission and has superior vWF:RCo function. Because recombinant vWF alone does not contain FVIII, when starting treatment of acute bleeding an FVIII concentrate is administered additionally and separately, or a combination product is used. The dose is calculated in vWF:RCo units (IU/kg), and the target level is determined by the bleeding situation and type of surgery.

Adjunctive treatment and management of special situations

Tranexamic acid is an antifibrinolytic that prevents clot lysis by inhibiting plasminogen activation, and is used together with vWF concentrates or DDAVP for treatment of mucosal bleeding (epistaxis, gum bleeding, oral surgery, heavy menstrual bleeding). Combined oral contraceptives exert a dual effect in female patients: the estrogen component stimulates vWF production and raises vWF:Ag, while stabilizing the endometrium to control heavy menstrual bleeding. Pregnancy management: vWF and FVIII:C rise physiologically in the third trimester, so most type 1 patients can achieve hemostasis at delivery without special treatment, but delayed bleeding may occur owing to a sharp postpartum decrease in vWF, so postpartum monitoring is needed. In type 3 and severe type 2, a plan for using vWF concentrates before delivery should be established in advance.


11. Prognosis

Prognosis of vWD types 1 and 2

In vascular haemophilia (vWD) type 1 and most type 2 subtypes, with appropriate diagnosis and treatment life expectancy is normal and quality of life is largely preserved. With regular follow-up and a well-established pre-treatment plan before invasive procedures, most bleeding episodes can be prevented or rapidly controlled. In type 1 patients, vWF:Ag tends to rise physiologically somewhat with aging, so the bleeding tendency may ease in old age.

Special considerations in vWD type 3

In vWD type 3, both vWF and FVIII:C are extremely low, so spontaneous joint bleeding and muscle hematomas can recur. Recurrent joint bleeding that is untreated or whose treatment is delayed can cause joint damage similar to hemophilic arthropathy (synovial hypertrophy, cartilage destruction, joint deformity), leading to long-term decline in motor function and reduced quality of life. In addition, in patients with type 3 vWD, inhibitory antibodies (inhibitors) against vWF can form after repeated transfusions, in which case treatment becomes very complicated. In patients with vWF inhibitors, recombinant activated FVII (NovoSeven) or activated prothrombin complex concentrate (FEIBA) is used as bypassing agents.

Reproductive health of female patients

In female vWD patients, chronic iron deficiency anemia due to heavy menstrual bleeding is a common comorbid problem, and iron supplementation and menstrual management are important. Safe planning of pregnancy and delivery is a key element in the prognosis of female vWD patients, and in most cases safe delivery is possible if a delivery plan is established in close cooperation between a hematologist and an obstetrician-gynecologist.


12. Prevention

Genetic counseling and family screening

The first step of the preventive approach to vascular haemophilia is genetic counseling. Since vWD type 1 and types 2A/2B/2M are autosomal dominant, it should be explained that each child of a patient has a 50% chance of inheriting the variant. Since types 2N and 3 are autosomal recessive, the carrier status of both parents must be confirmed. Screening tests including vWF:Ag, vWF:RCo, and FVIII:C are performed on siblings and children within the family, and when necessary VWF gene analysis is used to confirm whether they carry the variant.

Prenatal diagnosis and DDAVP response test

In high-risk couples with severe vWD (type 3 or severe type 2), the birth of a child with the genetic disease can be prevented by prenatal diagnosis through chorionic villus sampling (CVS) or amniocentesis, or by preimplantation genetic testing (PGT) combined with in vitro fertilization. After diagnosis, a DDAVP response test is performed to determine each individual's treatment response in advance, and the treatment plan to be used for invasive procedures such as minor surgery and tooth extraction is individualized. For poor responders (types 2B, 2M, 2N, and 3, and some severe type 1), a prescription plan for vWF concentrates must be established in advance.

Daily life management and registration at specialized centers

Patients are educated to avoid routine use of drugs that inhibit platelet function (aspirin, nonsteroidal anti-inflammatory drugs, some antidepressants), and guided to consult their hematologist when use is unavoidable. Sports or activities with a high risk of trauma are advised individually according to the level of bleeding risk. In female patients, tranexamic acid or oral contraceptives are prescribed in advance to control heavy menstrual bleeding and prevent excessive bleeding at every menstrual cycle. Registering for rare disease Special Copayment Reduction (V009) and receiving continuous follow-up at a specialized hemophilia/vWD treatment center is the most important practice for long-term prevention and maintaining quality of life.


13. References

  1. von Willebrand EA. Hereditär pseudohemofili. Finska Läkaresällsk Handl. 1926;68:87-112.
  2. Leebeek FW, Eikenboom JC. Von Willebrand's disease. N Engl J Med. 2016;375(21):2067-2080.
  3. Sadler JE, Budde U, Eikenboom JC, et al. Update on the pathophysiology and classification of von Willebrand disease: a report of the Subcommittee on von Willebrand Factor. J Thromb Haemost. 2006;4(10):2103-2114.
  4. Nichols WL, Hultin MB, James AH, et al. von Willebrand disease (VWD): evidence-based diagnosis and management guidelines, the National Heart, Lung, and Blood Institute (NHLBI) Expert Panel report (USA). Haemophilia. 2008;14(2):171-232.
  5. Mannucci PM. Treatment of von Willebrand's disease. N Engl J Med. 2004;351(7):683-694.
  6. Castaman G, Lethagen S, Federici AB, et al. Principles of care for the diagnosis and treatment of von Willebrand disease. Haematologica. 2013;98(5):667-674.
  7. Federici AB, Mannucci PM, Castaman G, et al. Clinical and molecular predictors of thrombocytopenia and risk of bleeding in patients with von Willebrand disease type 2B: a cohort study of 67 patients. J Thromb Haemost. 2009;7(4):572-579.
  8. James AH, Manco-Johnson MJ, Yawn BP, Dietrich JE, Nichols WL. Von Willebrand disease: key points from the 2008 National Heart, Lung, and Blood Institute guidelines. Obstet Gynecol. 2009;114(3):674-678.
  9. Ruggeri ZM, Zimmermann TS. The complex multimeric composition of factor VIII/von Willebrand factor. Blood. 1981;57(6):1140-1143.
  10. Zimmermann TS, Ratnoff OD, Powell AE. Immunologic differentiation of classic hemophilia (factor 8 deficiency) and von Willebrand's disease, with observations on combined deficiencies of antihemophilic factor and proaccelerin (factor V) and on an acquired circulating anticoagulant against antihemophilic factor. J Clin Invest. 1971;50(1):244-254.